anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Use of a compound of general formula (I) or salt thereof wherein R and R4 are independently selected from hydrogen, halogen and C¿1-6? alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl, C1-6 alkoxy, phenoxy, C1-6 alkylthio, phenylthio, primary and secondary amino or hydroxy groups and R?3¿ is hydrogen, hydroxy, a C¿1-6? alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl or C1-6 alkoxy or haloalkoxy group is provided for the manufacture of a medicament for the treatment of neoplasms, particularly solid cancerous tumours characterised in that R?1¿ is selected from a C¿1-6? alkyl or haloalkyl group, -CO2R?5¿ where R5 is hydrogen or a C¿1-6? alkyl or haloalkyl group, or a group -CH2-X where X is selected from groups of formula -S-R?6, -O-R6¿, and (a) where R6 is a hydrogen or a leaving group, the acid HR6 of which has a pKa of 10 or less and R?7 and R8¿ are the same or different and are selected from C¿1-6? alkyl or haloalkyl or together with the interjacent nitrogen form a heterocyclic ring of 5 to 7 atoms optionally substituted by C1-4 alkyl or haloalkyl and R?2¿ is selected from hydrogen, C¿1-4? alkyl and haloalkyl or groups-(CH2)nCHR?9R10¿ of more than four carbon atoms where n is an integer of 0 to 2 and R?9 and R10¿ are independently selected from a C¿1-4? alkyl or haloalkyl group, or R?9 and R10¿ together with the interjacent carbon atom form a C¿3-7? cycloalkyl or cycloalkenyl ring optionally substituted with one or more C1-4 alkyl or haloalkyl, or C2-4 alkenyl or haloalkenyl groups.
Improved method and apparatus for neutron capture therapy are disclosed, which may beneficially be used to counteract restenosis. An improved stent and a method for manufacturing the stent are also presented. The stent comprises a stable nuclide having a large neutron capture cross-section. When a clinical need exists for radiation therapy, the stent is irradiated with thermal neutrons, thereby giving rise to radiation in the proximity of the stent to a therapeutic benefit. Since radiation is applied by an external source, it can be delivered at any time after placement of the stent and easily can be repeated. The stent only contains stable nuclides and therefore can be handled without the precautions needed when handling radioactive matter.
The present invention discloses a preparation process of a traditional Chinese medicine mirabilite which contains fine particles with strong water-absorbing capacity and is used for external application. Clinical studies show that the mirabilite (Na2SO410H2O) and the powder mirabilite (Na2SO4) have no water-absorbing capacity. Dry mirabilite has weaker water-absorbing capacity, which is not suitable for direct external application as the anti-inflammatory drug. The dry traditional Chinese medicine mirabilite is smashed into the fine particles of the mirabilite, although the invention has strong water-absorbing capacity, the invention can generate free water during the smashing process, which can generate the clotting phenomenon after a short time of placement, thus the invention is difficult to use and can not be stored. The dry fine particles of the mirabilite has strong water-absorbing capacity, which can be used for treating a variety of inflammatory diseases by external applicationafter the invention is packaged by the gauze with good gas permeability, so the preparation of the dry fine particles of the mirabilite which has strong water-absorbing capacity and is easy to package, store and use is necessary. The present invention discloses a process to prepare the dry fine particles of the traditional Chinese medicine mirabilite crystal which has strong water-absorbing capacity by a variety of sectional air drying, smashing and screening.
NEW MATERIAL:The OM-173alpha2 substance of formula (R is COOCH3) and OM- 173beta2 substance (R is CH2OH). USE:An antimicrobial agent active against eumycetes and mycoplasma. PROCESS:A bacterial strain belonging to Streptomyces genus and capable of producing OM-173alpha2 substance and OM-173beta2 substance, e.g. Streptomyces sp. OM-173 (FERM-P No.6509), is cultured, and the produced and accumulated objective compound is separated. The cultivation is carried out in a conventional medium under aerobic conditon under shaking or in an aerated and agitated deep-tank fermentor usually at 20-35 deg.C for 100-150hr. After the completion of culture, the product is filtered to separate the microbial cells, and the filtrate is extracted with an organic solvent and subjected to silica-gel chromatography, etc., to obtain the purified substance of formula.
###  In Combination

Daunorubicin hydrochloride injection 45 mg/m 2/day IV on days 1, 2, and 3 AND vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m 2/day PO on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500 IU/kg/day x 10 days IV on days 22 through 32. 

The sterile vial contents provide 20 mg or 50 mg of daunorubicin, with 5 mg of daunorubicin per mL. The desired dose is withdrawn into a syringe containing 10 mL to 15 mL of 0.9% Sodium Chloride Injection, USP and then injected into the tubing or sidearm in a rapidly flowing IV infusion of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP. Daunorubicin hydrochloride injection should not be administered mixed with other drugs or heparin.

###  Storage and Handling

Store unopened vials in refrigerator, 2° to 8°C (36° to 46°F). Store prepared solution for infusion at room temperature, 15° to 30°C (59° to 86°F) for up to 24 hours. Contains no preservative. Discard unused portion. Protect from light.

If daunorubicin hydrochloride injection contacts the skin or mucosae, the area should be washed thoroughly with soap and water. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1-7 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
Most tumors are caused by inherited or acquired genetic changes. However, a subset of tumors is driven by viral infection including Kaposi sarcoma, nasopharyngeal carcinoma, and others. Human papillomavirus (HPV) is an especially common cause of epithelial cancers and hyperplasias. Epidermodysplasia verruciformis (EDV) is a rare type of HPV infection with characteristic histopathologic features and a unique spectrum of HPV subtypes. We report here a distinctive form of EDV-associated eccrine neoplasia. Seven tumors from two patients were analyzed and show highly uniform features including multiple clustered clinical lesions, multifocal epidermal origin, eccrine differentiation with close association with the acrosyringium, an anastomosing growth pattern, and a bland monotonous poroid-to-basaloid cytomorphology. Clinical follow-up for one patient has been benign to date. These tumors show strong similarity to two previously reported cases, suggesting that this type of EDV-associated eccrine neoplasia may represent a rare but reproducible form of skin adnexal tumor with distinctive clinicopathologic features.
The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
BACKGROUND: Clinical practice guidelines (CPGs) synthesize high-quality information to support evidence-based clinical practice. In primary care, numerous CPGs must be integrated to address the needs of patients with multiple risks and conditions. The BETTER program aims to improve prevention and screening for cancer and chronic disease in primary care by synthesizing CPGs into integrated, actionable recommendations. We describe the process used to harmonize high-quality cancer and chronic disease prevention and screening (CCDPS) CPGs to update the BETTER program.
METHODS: A review of CPG databases, repositories, and grey literature was conducted to identify international and Canadian (national and provincial) CPGs for CCDPS in adults 40-69 years of age across 19 topic areas: cancers, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, hepatitis C, obesity, osteoporosis, depression, and associated risk factors (i.e., diet, physical activity, alcohol, cannabis, drug, tobacco, and vaping/e-cigarette use). CPGs published in English between 2016 and 2021, applicable to adults, and containing CCDPS recommendations were included. Guideline quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool and a three-step process involving patients, health policy, content experts, primary care providers, and researchers was used to identify and synthesize recommendations.
RESULTS: We identified 51 international and Canadian CPGs and 22 guidelines developed by provincial organizations that provided relevant CCDPS recommendations. Clinical recommendations were extracted and reviewed for inclusion using the following criteria: 1) pertinence to primary prevention and screening, 2) relevance to adults ages 40-69, and 3) applicability to diverse primary care settings. Recommendations were synthesized and integrated into the BETTER toolkit alongside resources to support shared decision-making and care paths for the BETTER program.
CONCLUSIONS: Comprehensive care requires the ability to address a person's overall health. An approach to identify high-quality clinical guidance to comprehensively address CCDPS is described. The process used to synthesize and harmonize implementable clinical recommendations may be useful to others wanting to integrate evidence across broad content areas to provide comprehensive care. The BETTER toolkit provides resources that clearly and succinctly present a breadth of clinical evidence that providers can use to assist with implementing CCDPS guidance in primary care.
In recent years, a surge in studies investigating N6-methyladenosine (m6A) modification in human diseases has occurred. However, the specific roles and mechanisms of m6A in kidney disease remain incompletely understood. This study revealed that m6A plays a positive role in regulating renal fibrosis (RF) by inducing epithelial-to-mesenchymal phenotypic transition (EMT) in renal tubular cells. Through comprehensive analyses, including m6A sequencing, RNA-seq, and functional studies, we confirmed the pivotal involvement of zinc finger E-box binding homeobox 2 (ZEB2) in m6A-mediated RF and EMT. Notably, the m6A-modified coding sequence of ZEB2 mRNA significantly enhances its translational elongation and mRNA stability by interacting with the YTHDF1/eEF-2 complex and IGF2BP3, respectively. Moreover, targeted demethylation of ZEB2 mRNA using the dm6ACRISPR system substantially decreases ZEB2 expression and disrupts the EMT process in renal tubular epithelial cells. In vivo and clinical data further support the positive influence of m6A/ZEB2 on RF progression. Our findings highlight the m6A-mediated regulation of RF through ZEB2, revealing a novel therapeutic target for RF treatment and enhancing our understanding of the impact of mRNA methylation on kidney disease.
A medical device comprising radiopaque water-dispersible metallic nanoparticles, wherein the nanoparticles are released from the medical device upon implantation of the device. The medical device of the present invention is sufficiently radiopaque for x-ray visualization during implantation, but loses its radiopacity after implantation to allow for subsequent visualization using more sensitive imaging modalities such as CT or MRI. 
     The nanoparticles are formed of a metallic material and have surface modifications that impart water-dispersibility to the nanoparticles. The nanoparticles may be any of the various types of radiopaque water-dispersible metallic nanoparticles that are known in the art. The nanoparticles may be adapted to facilitate clearance through renal filtration or biliary excretion. The nanoparticles may be adapted to reduce tissue accumulation and have reduced toxicity in the human body. The nanoparticles may be applied directly onto the medical device, e.g., as a coating, or be carried on the surface of or within a carrier coating on the medical device, or be dispersed within the pores of a porous layer or porous surface on the medical device. The medical device itself may be biodegradable and may have the nanoparticles embedded within the medical device itself or applied as or within a coating on the biodegradable medical device. The nanoparticles may be released by diffusion through the carrier coating, disruption of hydrogen bonds between the nanoparticles and the carrier coating, degradation of the nanoparticle coating, degradation of the carrier coating, diffusion of the nanoparticles from the medical device, or degradation of the medical device carrying the nanoparticles.
PURPOSE:The titled suppository for promoting blood circulation at the affected part of hemorrhoids by heat generation, effective for alleviating and remedying symptoms of hemorrhoids, containing a substance which is brought into contact with oxygen or water to generate heat as an active ingredient. CONSTITUTION:The titled suppository containing a substance (e.g., iron powder, iron fiber, aluminum powder, etc.) which is brought into contact with oxygen or water to generate heat as an active ingredient. Preferably 1-10wt% of the heat-generating substance is contained in a suppository. In remedying hemorrhoids, it is most effective to warm extremely limited affected part of hemorrhoids, and hemorrhoids can be effectively remedied by the titled suppository blended with the heat-generating substance. Further, addition of a water- insoluble high polymer compound (e.g., cross-linking type polyacrylic acid resin, etc.) to the heat-generating substance can control heat generation, and prolong heat generation time more effectively.
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) represent 1-2% of pancreatic tumors, with recent guidelines recommending active surveillance for non-functioning PNETs (NF-PNETs) smaller than 2 cm. However, the management of multiple NF-PNETs, as well as the influence of tumor number on prognosis, remains under-researched.
METHODS: This retrospective study analyzed NF-PNET patients who underwent pancreatic resection at Severance Hospital between February 1993 and August 2023, comparing the characteristics of patients diagnosed with multifocal tumors and those with unifocal tumors. A subgroup analysis of overall survival (OS) and recurrence-free survival (RFS) was performed based on multifocality employing the Kaplan-Meier method and the log-rank test.
RESULTS: Of 187 patients, 169 (90.4%) had unifocal and 18 (9.6%) had multifocal tumors. Multifocal tumors were more likely to be diffusely spread, necessitating more total pancreatectomies (diffuse tumor location: 4.7% in unifocal vs. 38.9% in multifocal cases, p < 0.001; total pancreatectomy: 4.1% in unifocal vs. 33.3% in multifocal cases, p < 0.001). In patients with NF-PNET who underwent the same extent of pancreatic resection, no significant difference in the incidence of complication was observed regardless of multifocality. Moreover, no significant difference in OS was seen between the unifocal and multifocal groups (log-rank test: p = 0.93). However, the multifocal group exhibited a poorer prognosis in terms of RFS compared to the unifocal group (log-rank test: p = 0.004) Hereditary syndrome, tumor grade, size, lymphovascular invasion, and lymph node metastasis were key factors in the recurrence.
CONCLUSION: This study's findings suggest that the presence of multiple tumors was associated with poorer recurrence-free survival but did not affect long-term survival following surgery. Given the long-term oncologic outcome and quality of life following surgery, resection of tumors over 2 cm is advisable in patients with multifocal PNETs, while a cautious "wait-and-see" approach for smaller tumors (under 2 cm) can minimize the extent of resection and improve the quality of life. In cases with only small multifocal NF-PNETs (< 2 cm), immediate resection may not be crucial, but the higher recurrence rate than that in solitary NF-PNET necessitates intensified surveillance.
Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that typically causes rapidly progressive muscle weakness, disability and premature death. In spite of a large number of attempted ALS trials, there are no significant disease-modifying therapies for this condition to-date.

There exists a small group of patients who meet diagnostic criteria for ALS or progressive muscular atrophy (PMA), progress for a period of time, and then significantly improve. Some of these "ALS reversals" even make a complete recovery back to normal neurological function. The investigator has independently verified 34 of these cases so far through review of medical records and peer-reviewed literature. These patients are different in their demographics and disease characteristics as compared to patients with more typically progressive ALS. One possible explanation for these cases is that these patients are genetically different than most patients with ALS and that these differences confer a form of disease "resistance". Study of these selected reversal patients may yield valuable clues to endogenous mechanisms of ALS resistance. The concept of genetic conferred ability to resist a disease is not novel. A group of patients who could unexpectedly "control" HIV due to a mutant allele has led to an improved understanding of HIV pathophysiology and a new treatment

This is a pilot case-control study attempting to discover genetic correlates to ALS reversals. The investigator will collect demographics, disease characteristics, pedigree information and saliva samples from ALS reversals. Whole genome DNA will be extracted and sequenced from these saliva samples. The genomes of ALS reversals will then be compared with whole genome sequencing previously completed from a biorepository of de-identified samples of more typically progressive patients with ALS. The study will not save any saliva samples collected as a part of this new protocol for future research.
Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
Coagulation disorders are one of the most common complications in critically ill patients. Among them deep vein thrombosis and pulmonary embolism are the most significant factors increasing morbidity and mortality in ICU patients. Use of anticoagulant prophylaxis aims to prevent these dangerous complications. Most commonly used anticoagulant prophylaxis agents are low molecular weight heparins (LMWH). LMWH therapeutic efficiency is measured with activity of anti-Xa factor, that should range between 0.2 and 0.4 IU/mL in order to prevent thrombotic complications. Due to grave general condition, critically ill patients may often develop acute kidney injury (AKI), that requires renal replacement therapy (RRT). Because of haemodynamic instability the safest therapeutic choice seems to be continuous veno-venous hemodiafiltration (CVVHDF). This RRT mode removes particles in the size of few daltons even up to 10 kilodaltons (kDa) such as metabolic product waste, ions, hormones etc. LMWH with average molecular weight of 4.5 kDa and fondaparinux with average molecular weight of 1.7 kDa may be removed during CVVHDF resulting in insufficient activity of anti-Xa factor thus increasing the risk of thrombotic complications in critically ill patients.
As with other NSAIDs, anaphylactic reactions may occur both in patients with the aspirin triad and in patients without known sensitivity to NSAIDs or known prior exposure to diclofenac. Diclofenac should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs. [See Contraindications and Precautions, Preexisting Asthma]. Anaphylaxis-type reactions have been reported with NSAID products, including with diclofenac products, such as Diclofenac Sodium. Emergency help should be sought in cases where an anaphylactic reaction occurs.
All patients will receive active treatment which consists of stimulation (tDCS) applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents).
OBJECTIVE: Japan has a system of occupational therapy programs known as self-reliance training (training for daily living), which helps people with various disabilities lead more meaningful lives. Recently, it has been shown that green care farms are beneficial for dementia care and that agricultural and horticultural work has a positive impact on people with intellectual disabilities and mental disorders. This study examined the health-improving effects of farm activities and developed an attractive program for adolescents with developmental and intellectual disabilities who use independent training facilities. The program comprised agricultural and horticultural activities such as vegetable cultivation and management, flower planting, and flower arrangement.
RESULTS: No significant differences were observed in any of the measures for positive mood before and after the usual program (UP). However, anger-hostility and depression-dejection improved significantly after the farm program (FP) (p < .05). Self-efficacy improved significantly after both UP and FP (p < .10). Free responses were obtained from UP (131 responses) and FP (126 responses) participants; thematic analysis of FP participants' statements revealed that positive comments included "confidence in accomplishing tasks," "anticipation and joy of growing plants," and "motivation for gardening activities."
The present invention provides a medicine treating the diabetes and the complication as well as the preparation method. The medicine comprises the berberidis, the potentially discolour and the called millennial. The compatibility weight composition of the medicine comprises 20g to 50g berberidis, 20g to 50g potentillae discoloris and 20g to 60g caulis millettiae. The medicine of the present invention can be prepared by water extraction method with or without the alcohol extraction method. Compared with the present synthetic drug, the present invention has advantages of excellent safety property. Compared with the present Chinese herb, the present invention has properties of significant effect in reducing blood sugar level and preventing the complication of diabetes. The present invention can be produced as various kinds of proper preparation type for clinical application.